Immune system adaptation during gender-affirming testosterone treatmentKarolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Institut Pasteur, Université Paris Cité, Translational Immunology Unit, Paris, France.
Karolinska Institutet, Department of Medicine Solna, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Department of Medicine Solna, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden.
Umeå University, Department of Public Health and Clinical Medicine, Umeå, Sweden.
Karolinska University Hospital, ANOVA, Stockholm, Sweden; Karolinska Institutet, Department of Medicine Huddinge, Stockholm, Sweden.
Karolinska University Hospital, ANOVA, Stockholm, Sweden; Karolinska Institutet, Department of Medicine Huddinge, Stockholm, Sweden.
Karolinska Institutet, Endocrinology and Diabetes Unit, Department of Molecular Medicine and Surgery, Solna, Sweden.
Uppsala University, Department of Medical Sciences, Uppsala, Sweden.
Institut Pasteur, Université Paris Cité, Translational Immunology Unit, Paris, France.
Karolinska Institutet, Department of Medicine Solna, Solna, Sweden; Karolinska University Hospital, Center of Molecular Medicine, and Department of Endocrinology, Metabolism and Diabetes, Stockholm, Sweden.
Karolinska Institutet, Department of Medicine Solna, Solna, Sweden; Uppsala University, Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala, Sweden.
Karolinska Institutet, Unit for Clinical Pediatrics, Dept. of Women’s and Children’s Health, Solna, Sweden; Imperial College London, Department of Immunology and Inflammation, London, UK.
Show others and affiliations
2023 (English)In: Journal of Reproductive Immunology, ISSN 0165-0378, E-ISSN 1872-7603, Vol. 159, p. 29-30Article in journal, Meeting abstract (Other academic) Published
Abstract [en]
Biological sex impacts human immune responses, modulating susceptibility and severity to immune-related diseases. Female generally mount more robust immune responses than males, resulting in lower infection severity and greater autoimmunity incidence. Here, we addressed the contribution of testosterone to human immune function by analyzing a cohort of subjects undergoing gender-affirming testosterone treatment. We performed systems-level immunomonitoring through mass cytometry, scRNA and scA-TAC-Sequencing, and proteome profiling of blood samples at baseline and following 3 and 12 months of treatment. Testosterone treatment was associated with a low-grade inflammatory profile, evidenced by upregulation of proinflammatory plasma proteome (e.g., EN-RAGE, OSM, TNF), and induction of an inflammatory transcriptional program associated with NFkB signaling, and TNF signaling. Following testosterone treatment, higher NFkB activity was revealed in CD4 T, CD8 T, and NK cells in scATACseq analyses. Further, testosterone increased monocytic inflammatory responses upon bacterial stimulation in vitro. Although testosterone was associated with this inflammatory profile, it also exerted negative effects on antiviral immunity. Firstly, the percentage of plasmacytoid dendritic cells (pDC) decreased over transition, with pDC also displaying phenotypic changes associated with lower IFN responses. Secondly, bulk transcriptomics analyses show an overall reduction of IFNa responses. Thirdly, testosterone treatment led to reduced IFNa production upon PBMCs stimulation with a viral agonist. Our results show that testosterone has broad effects on the human immune system, and significantly modulates important players in antiviral immunity and inflammatory response. Identifying pathways involved in immune sexual dimorphism will help define novel targets for effective prevention and treatment of immune-mediated diseases.
Place, publisher, year, edition, pages
Elsevier, 2023. Vol. 159, p. 29-30
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:oru:diva-109078DOI: 10.1016/j.jri.2023.104065ISI: 001069722400073OAI: oai:DiVA.org:oru-109078DiVA, id: diva2:1806253
Conference
12th International Workshop Reunion Island Reproductive Immunology, Immunological tolerance and Immunology of preeclampsia, Electronic Network, December 12-15, 2022
2023-10-202023-10-202023-10-20Bibliographically approved